The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Open accessAbstract
Purpose: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells to kill gp100-expressing tumor cells. Here, we report a multicenter phase I/II trial of tebentafusp in metastatic melanoma (NCT01211262) focusing on the mechanism of action of tebentafusp. Patients and Methods: Eighty-four patients with advanced melanoma received tebentafusp. Treatment efficacy, treatment-related adverse events, and biomarker assessments were performed for blood-derived and tumor biopsy samples obtained at baseline and on-treatment. Results: Tebentafusp was generally well-tolerated and active in both patients with metastatic uveal melanoma and patients with metastatic cutaneous melanoma. A 1-year overall survival rate of 65% was achieved for both patient cohorts. On-treatment cytokine measurements were consistent with the induction of IFNγ pathway–related markers in the periphery and tumor. Notably, tebentafusp induced an increase in serum CXCL10 (a T-cell attractant) and a reduction in circulating CXCR3+ CD8+ T cells together with an increase in cytotoxic T cells in the tumor microenvironment. Furthermore, increased serum CXCL10 or the appearance of rash (likely due to cytotoxic T cells targeting gp100-expressing skin melanocytes) showed a positive association with patient survival. Conclusions: These data suggest that redirecting T cells using a gp100-targeting TCR/anti-CD3 bispecific fusion protein may provide benefit to patients with metastatic melanoma. Furthermore, the activity observed in these two molecularly disparate melanoma classes hints at the broad therapeutic potential of tebentafusp.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035
Statistical Methods in Medical Research
Armitage, P., Berry, G., & Matthews, J. N. S. (2002) · Wiley eBooks · doi:10.1002/9780470773666 · Cited by 1,630
Groom, J. R., & Luster, A. D. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.12.017 · Cited by 988
T Cell Antigen Receptor Recognition of Antigen-Presenting Molecules
Rossjohn, J., Gras, S., Miles, J. J., Turner, S. J., Godfrey, D. I., & McCluskey, J. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112334 · Cited by 797
Chow, M. T., Ozga, A. J., Servis, R. L., Frederick, D. T., Lo, J. A., Fisher, D. E., Freeman, G. J., Boland, G. M., & Luster, A. D. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.010 · Cited by 716 · cited 1×
“A role of this axis in the sensitivity to anti–PD-1 therapy has also been indicated (25).”
BackgroundMetastatic disease from uveal melanoma: treatment options and future prospects
Carvajal, R. D., Schwartz, G. K., Tezel, T., Marr, B., Francis, J. H., & Nathan, P. D. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-309034 · Cited by 438
Cited by
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103485 · Cited by 924
Self-citationRecent Advances in the Treatment of Melanoma
Curti, B. D., & Faries, M. B. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2034861 · Cited by 386
Advances in the clinical management of uveal melanoma
Carvajal, R. D., Sacco, J. J., Jager, M. J., Eschelman, D. J., Olofsson Bagge, R., Harbour, J. W., Chieng, N. D., Patel, S. P., Joshua, A. M., & Piperno-Neumann, S. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00714-1 · Cited by 278
T-cell-engaging bispecific antibodies in cancer
van de Donk, N. W. C. J., & Zweegman, S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00521-4 · Cited by 267
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
Ny, L., Jespersen, H., Karlsson, J., Alsén, S., Filges, S., All-Eriksson, C., Andersson, B., Carneiro, A., Helgadottir, H., Levin, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25332-w · Cited by 177
Metadata
- Authors
- Middleton, M. R., McAlpine, C., Woodcock, V. K., Corrie, P., Infante, J. R., Steven, N. M., Evans, T. R. J., Anthoney, A., Shoushtari, A. N., Hamid, O., Gupta, A., Vardeu, A., Leach, E., Naidoo, R., Stanhope, S., Lewis, S., Hurst, J., O’Kelly, I., & Sznol, M.
- Venue
- Clinical Cancer Research
- Published
- 2020-11-13
- Volume
- 26
- Issue
- 22
- Pages
- 5869-5878
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W3072109384
- Cited by
- 275
- References
- 30
- FWCI
- 10.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-1247
- The paper
- Middleton, M. R., McAlpine, C., Woodcock, V. K., Corrie, P., Infante, J. R., Steven, N. M., Evans, T. R. J., Anthoney, A., Shoushtari, A. N., Hamid, O., Gupta, A., Vardeu, A., Leach, E., Naidoo, R., Stanhope, S., Lewis, S., Hurst, J., O’Kelly, I., & Sznol, M. (2020). Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-1247
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.